Autolus Therapeutics' (AUTL) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock.

AUTL has been the subject of several other reports. Wells Fargo & Company cut their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL traded down $0.03 during mid-day trading on Thursday, reaching $2.12. The stock had a trading volume of 1,894,889 shares, compared to its average volume of 1,564,203. The stock has a market capitalization of $564.22 million, a P/E ratio of -1.75 and a beta of 1.76. The firm has a 50 day moving average price of $1.55 and a two-hundred day moving average price of $1.94. Autolus Therapeutics has a one year low of $1.11 and a one year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. Research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC raised its stake in shares of Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock valued at $159,000 after acquiring an additional 91,222 shares during the last quarter. Armistice Capital LLC increased its holdings in Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock valued at $17,050,000 after purchasing an additional 1,800,000 shares during the period. Vident Advisory LLC bought a new position in Autolus Therapeutics during the 1st quarter valued at approximately $241,000. Tema Etfs LLC bought a new position in Autolus Therapeutics during the 1st quarter valued at approximately $171,000. Finally, Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 6.9% in the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock worth $41,992,000 after buying an additional 1,746,020 shares during the period. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.